NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market
The U.S. animal health market was valued at USD 12.65 billion in 2024 and is expected to grow at a CAGR of 7.97% from 2025 to 2030. This growth is believed to be a consequence of rising innovations surrounding companion animal pharmaceuticals, increasing millennial pet adoption rates, growing livestock populations and production in developing countries, and increasing meat or milk consumption rates, coupled with rising concerns about food-borne diseases. (1)
Northstrive Biosciences Inc.'s amendment to its existing licensing agreement allows the company to develop and commercialize a comprehensive range of animal health products, including pharmaceuticals and feed additives. The company believes these products are essential for improving animal health, productivity, and overall food security.
NEWPORT BEACH, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the 'Company,' 'PMGC,' 'we,' or 'our') wholly owned subsidiary, NorthStrive Biosciences Inc. ('Northstrive Biosciences'), announced today a significant amendment ('Amendment') to an existing License Agreement with MOA Life Plus Co., Ltd., a Korean biotechnology company ('MOA,' and such existing agreement, 'License Agreement') Northstrive Biosciences holds for EL-32 and EL-22. This Amendment expands the scope of Northstrive Biosciences' license rights to all uses in animal health, including all applications as a feed additive.
The Company believes this expanded scope of its license rights with MOA will position NorthStrive Biosciences to potentially capture new revenue streams from high-growth markets and lower its barrier to entry within the animal health pharmaceutical sector. Northstrive Biosciences aims to capitalize on the growing demand for advanced and safe solutions to address unmet needs in the U.S. animal health market.
This strategic move enhances NorthStrive Biosciences' licensing portfolio and reinforces its mission to deliver groundbreaking health solutions with high commercial potential.
About NorthStrive Biosciences Inc.
NorthStrive Biosciences Inc., a PMGC Holdings Inc. company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. NorthStrive's lead asset, EL-22, leverages an engineered probiotic approach to address obesity's pressing issue of preserving muscle while patients are on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com.
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. Currently, our portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as 'believes,' 'expects,' 'plans,' 'potential,' 'would' and 'future' or similar expressions such as 'look forward' are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC Holdings' filings with the United States Securities and Exchange Commission ('SEC'), including the 'Risk Factors' section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Ondas Holdings Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BOSTON, MA / / June 9, 2025 / Ondas Holdings Inc. (NASDAQ:ONDS) ("Ondas" or the "Company"), a leading provider of private industrial wireless networks and commercial drone and automated data solutions through its Ondas Networks and Ondas Autonomous Systems business units, today announced that it intends to offer and sell shares of its common stock and in lieu of common stock, pre-funded warrants to purchase shares of its common stock. Ondas also expects to grant the underwriter a 30-day option to purchase additional shares of common stock offered in the public offering. All of the securities in the proposed offering are to be sold by Ondas. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Ondas intends to use the net proceeds from the proposed offering for general corporate purposes, including funding capital expenditures and providing working capital. Oppenheimer & Co. Inc. is acting as the sole underwriter for the offering. A shelf registration statement on Form S-3 (File No. 333-286642) relating to the securities to be issued in the proposed offering was filed with the Securities and Exchange Commission ("SEC") on April 18, 2025 and was declared effective on April 25, 2025. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC. The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained from Oppenheimer & Co. Inc. Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at (212) 667-8055, or by email at EquityProspectus@ Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the SEC's website at The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Forward-Looking Statements Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the completion and anticipated use of proceeds of the proposed offering. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties relate, among other things, to fluctuations in our stock price, changes in market conditions and satisfaction of customary closing conditions related to the proposed public offering. Our actual results, performance, or achievements, including our ability to conduct and complete a public offering of our common stock on terms acceptable to us or at all, could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as required by law. ContactsIR Contact for Ondas Holdings Inc.888.350.9994ir@ Media Contact for OndasEscalate PRondas@ Preston GrimesMarketing Manager, Ondas Holdings SOURCE: Ondas Holdings Inc. View the original press release on ACCESS Newswire
Yahoo
19 minutes ago
- Yahoo
Warner Bros. Discovery Stock Enjoys Big Jump, Then Promptly Fades After Split Announcement
Warner Bros. Discovery's plan to split into two publicly traded companies sent its stock price surging higher on Monday morning, with shares of WBD jumping 13% to $11.10 on the Nasdaq exchange only minutes after the opening bell. Those early gains started to fade by midday, though, with Warner Bros. Discovery's stock trading for $9.94 per share at 1 p.m. ET — up 1.30% from where it closed last week. Here is an up-to-the-minute look at WBD: On the year, WBD is down 6%, and the company's stock price has been more than sliced in half since it debuted on the Nasdaq in 2022 for $24.08 per share. That came after WarnerMedia and Discovery merged — a move that was met with a collective shrug from Wall Street analysts and investors from the start, with its stock price increasing 0.8% on April 11, 2022, its first day of trading. Now, three years later, WBD announced on Monday it will split into two companies, with one company focused on its global cable channels and another dedicated to its movie and streaming businesses. David Zaslav, president and CEO of WBD, will become president and CEO of Streaming & Studios, while Gunnar Wiedenfels, WBD's CFO, will serve as president and CEO of Global Networks. The separation is expected to be completed by mid-2026. 'By operating as two distinct and optimized companies in the future, we are empowering these iconic brands with the sharper focus and strategic flexibility they need to compete most effectively in today's evolving media landscape,' Zaslav said in a statement. The new Streaming & Studios operation will consist of Warner Bros. Television, Warner Bros. Motion Picture Group, DC Studios, HBO and HBO Max, in addition to their corresponding film and television libraries. Global Networks, meanwhile, will include international entertainment, sports and TV news brands such as CNN, TNT Sports, Discovery, Discovery+, Bleacher Report and European free-to-air channels. In related news, WBD investors last week voted to reject a $51.9 million compensation package for Zaslav. The post Warner Bros. Discovery Stock Enjoys Big Jump, Then Promptly Fades After Split Announcement appeared first on TheWrap. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
How major US stock indexes fared Monday, 6/9/2025
U.S. stocks drifted closer to their record as the world's two largest economies begin talks on trade that could help avoid a recession. The S&P 500 rose 0.1% Monday and is 2.3% below the record it reached in February. The Dow Jones Industrial Average was flat, and the Nasdaq composite rose 0.3%. Markets are waiting to hear what comes of trade talks between the United States and China taking place in London. Treasury yields slipped after a survey suggested consumers' expectations for coming inflation eased. Chinese stocks rose, while indexes were mixed across the rest of Asia and Europe. On Monday: The S&P 500 rose 5.52 points, or 0.1%, to 6,005.88. The Dow Jones Industrial Average fell 1.11 points, or less than 0.1%, to 42,761.76. The Nasdaq composite rose 61.28 points, or 0.3%, to 19,591.24. The Russell 2000 index of smaller companies rose 12.20 points, or 0.6%, to 2,144.45. For the year: The S&P 500 is up 124.25 points, or 2.1%. The Dow is up 217.54 points, or 0.5%. The Nasdaq is up 280.44 points, or 1.5%. The Russell 2000 is down 85.71 points, or 3.8%. Sign in to access your portfolio
